Radionuclide therapy via SSTR: future aspects from experimental animal studies

Area of Science:

• Oncology
• Nuclear Medicine
• Pharmacology

Background:

• Neuroendocrine tumors (NETs) often overexpress somatostatin (SS) receptors.
• Current therapeutic options for NETs require improvement.

Purpose of the Study:

• To review experimental animal studies on radionuclide therapy for NETs.
• To propose future directions for SS receptor-targeted radionuclide therapy.

Main Methods:

• Literature review of experimental animal studies.
• Analysis of strategies to enhance therapeutic efficacy and minimize toxicity.

Main Results:

• Individualized treatment approaches are crucial, involving SS analogues, radionuclides, and schedules.
• Methods to increase tumor uptake and retention include receptor upregulation.
• Strategies to enhance tumor response involve radionuclide selection, SS analogues, and combination therapies.
• Reducing side effects involves minimizing uptake in critical organs and normal tissue response.

Conclusions:

• Personalized radionuclide therapy holds promise for neuroendocrine tumors.
• Combination therapies with other agents can potentiate treatment effects.
• Further research is needed to optimize SS receptor-targeted radionuclide therapy.